2020•Kidney International ReportsOpen access

SUN-018 Exploring an affordable option for induction therapy for live donor kidney Transplantation- r-ATG (Anti thymocyte globulin) vs. low dose e-ATG Therapy in Sri Lanka

H. Sheriff, R. Sheriff, S. heiyanthuduwa, Lalitha Piyarisi, Ranjuka Arushana Ubayasiri, K. umashanka, A. marasingha

Abstract

Induction therapy in the early post-transplant period has become a universally accepted method to get better outcomes in transplantation. ATG is being used widely especially in high risk transplantation. Antithymocyte globulin (ATG) is a poly clonal antibody that is used as induction therapy to treat acute rejection, It is a mixture of non-specific anti-lymphocyte immunoglobullins targeting T cell subsets and several immune and none immune cells. There are 2 types of ATG. r-ATG (rabbit) and e-ATG (equine) in comparison to other induction therapies like basiliximab, diclizumab and newer agents like alamtuzumab.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Basiliximab, Medicine, Anti-thymocyte globulin, Induction therapy, Transplantation, Globulin, Immunology, Immune system